HealthEquity Outperforms Establishment Labs in Key Metrics

Analysts see more upside potential in Establishment Labs despite HealthEquity's operational advantages.

Mar. 30, 2026 at 10:37am

Got story updates? Submit your updates here. ›

HealthEquity (NASDAQ:HQY) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but a comparison of their financial performance, institutional ownership, and analyst recommendations suggests HealthEquity is the stronger investment overall despite Establishment Labs having higher potential upside.

Why it matters

This analysis provides investors with a detailed look at the relative strengths and weaknesses of these two healthcare technology companies, helping them make more informed decisions about where to allocate their capital.

The details

HealthEquity has higher revenue, earnings, and profitability metrics compared to Establishment Labs. It also has stronger institutional ownership and lower stock price volatility. However, analysts see more potential upside in Establishment Labs' share price, likely due to its focus on the growing aesthetic and reconstructive surgery market.

  • The analysis is based on the latest financial data reported as of March 30, 2026.

The players

HealthEquity, Inc.

A provider of technology-enabled services platforms that help consumers manage healthcare savings and spending accounts.

Establishment Labs Holdings Inc.

A medical technology company that manufactures and markets silicone gel-filled breast implants and other aesthetic and reconstructive surgery products.

Got photos? Submit your photos here. ›

What they’re saying

“HealthEquity beats Establishment Labs on 11 of the 15 factors compared between the two stocks.”

— Alphonse Anthony, Author

“Given Establishment Labs' higher possible upside, analysts plainly believe Establishment Labs is more favorable than HealthEquity.”

— Alphonse Anthony, Author

The takeaway

While HealthEquity has demonstrated stronger operational performance, Establishment Labs' focus on the growing aesthetic and reconstructive surgery market appears to offer investors more potential upside according to analyst projections. Investors should carefully weigh both companies' fundamentals and growth prospects when making investment decisions.